ReviewReviews in endocrine & metabolic disorders2001
Mechanism of action and preclinical profile of raloxifene, a selective estrogen receptor modulation.
Review in Reviews in endocrine & metabolic disorders, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 48 citations in OpenAlex.
- Anti-fibrotic effect of a selective estrogen receptor modulator in systemic sclerosis.Stem cell research & therapy · 2022Article
- Raloxifene-loaded SLNs with enhanced biopharmaceutical potential: QbD-steered development, in vitro evaluation, in vivo pharmacokinetics, and IVIVC.Drug delivery and translational research · 2022Article
- Article
- 6'-Methoxy Raloxifene-analog enhances mouse bone properties with reduced estrogen receptor binding.Bone reports · 2020Article
- Article
- A Free Web-Based Protocol to Assist Structure-Based Virtual Screening Experiments.International journal of molecular sciences · 2019Article
- Facial Sadness Recognition is Modulated by Estrogen Receptor Gene Polymorphisms in Healthy Females.Brain sciences · 2018Article
- Online structure-based screening of purchasable approved drugs and natural compounds: retrospective examples of drug repositioning on cancer targets.Oncotarget · 2018Article
- Article
- Article
- Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene.Expert opinion on pharmacotherapy · 2011Review
- Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis.Therapeutics and clinical risk management · 2009Article
- Safety profile of raloxifene as used in general practice in England: results of a prescription-event monitoring study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2005Article
- Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.Drug safety · 2005Review
- Skeletal and nonskeletal effects of raloxifene.Current osteoporosis reports · 2003Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Raloxifene possesses a complex pharmacology with tissue-selective estrogen agonist and antagonist effects. At the center of these effects resides the high affinity interaction of raloxifene with the ER. The ability of raloxifene to compete with estrogen for ER binding accounts for the estrogen antagonist effects of raloxifene in uterine and mammary tissue. Since the precise mechanism for the agonist effect of estrogen on the skeleton remains uncertain, it is difficult to unequivocally cite a single estrogen-like mechanism for raloxifene in bone. However, multiple lines of evidence clearly indicate that the estrogen agonist effect of raloxifene on bone is also mediated via an interaction with ER. The data showing non-additivity of raloxifene and estrogen effects in bone, and those showing the requirement for a pituitary hormone in the anti-estrogenic action of raloxifene and estrogen are particularly important. Thus, global evaluation of the similarities and parallel responses of raloxifene and estrogen in bone and the cardiovascular system, as summarized above, strongly support a similar mechanistic basis for the agonist effects of these agents on the skeleton.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.